Deaths / year
200
GBD (indicative unless refreshed)
DALYs / year
300,000
GBD
Pathogen
Virus
Post-infectious
Post-infectious syndrome
Persistent symptoms
~40%
symptomatic cases
WHO groups dengue+chikungunya as one NTD entry; split here.
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Documented post-infectious syndrome
Chronic chikungunya arthritis / chronic inflammatory rheumatism
~40%
persistent symptoms — of symptomatic cases
Summary
Persistent arthralgia >=3 months in a pooled ~40% (95% CI 31-49%); cohort range 7-79%; Americas meta-analyses up to 52%.
Timeframe
months to years post-acute
Evidence strength
strong (multiple meta-analyses)
Classification
Post-infectious syndrome
Sources: Rodriguez-Morales 2016 (pooled 40%); Bonifay 2024 Lancet Infect Dis; Paixao 2018 (43% >3 mo); Webb 2024 PLoS Negl Trop Dis (44% chronic)
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Aedes vector control (source reduction, larvicides) | Vector control | Approved | Same vectors as dengue; integrated control | WHO |
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Vimkunya (VLA1553) vaccine | Vaccine | Approved | Live-attenuated chikungunya vaccine (FDA 2025) | FDA / published trials |
| Travel & exposure precautions | Prevention | Approved | Repellents, outbreak avoidance | WHO EML / standard of care |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Supportive care (rest, fluids) | Supportive | Approved | No approved antiviral; symptomatic management | WHO EML / standard of care |
| NSAIDs for acute arthralgia | Analgesic | Approved | First-line acute joint pain | WHO chikungunya |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Methotrexate / short corticosteroids | Immunomodulator | Approved | Chronic inflammatory rheumatism refractory to NSAIDs | Published cohorts |
| HydroxychloroquinePipeline | Antimalarial | Phase 2 | Investigational for chronic arthralgia | Clinical trials |
| Physiotherapy & joint rehabilitation | Rehabilitation | Approved | Persistent arthralgia and disability | WHO EML / standard of care |
Associated drug targets (Open Targets): GPR161, CD40LG
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: EFO_0008494 · Updated 2026-07-10. Associations, not a diagnostic test.